Clinical, cosmetic and investigational dermatology · 2022
Tofacitinib for Prurigo Nodularis: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peng Changlan, Li Chunxiao, Zhou Yingying, Wang Qiuyue, Xie Ping, Li Tianhao, Hao Pingsheng
Аннотация
PURPOSE: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored.
PATIENTS AND METHODS: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.
RESULTS: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis.
CONCLUSION: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.
PATIENTS AND METHODS: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.
RESULTS: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis.
CONCLUSION: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.